NICE urged to recommend anastrozole for breast cancer preventionBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f7458 (Published 13 December 2013) Cite this as: BMJ 2013;347:f7458
- Jacqui Wise
- 1 London
The aromatase inhibitor anastrozole reduces the incidence of breast cancer in high risk postmenopausal women, a large international study has shown.1 Because the drug has fewer side effects than tamoxifen, the researchers have called on the UK National Institute for Health and Care Excellence (NICE) to recommend it for prevention in women at high risk of breast cancer.
The International Breast Cancer Intervention Study II (IBIS-II) trial recruited almost 4000 postmenopausal women with an increased risk of cancer, such as women who had a mother or sister who developed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial